Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

Sid E. O'Bryant, Michelle M. Mielke, Robert A. Rissman, Simone Lista, Hugo Vanderstichele, Henrik Zetterberg, Piotr Lewczuk, Holly Posner, James Hall, Leigh Johnson, Yiu Lian Fong, Johan Luthman, Andreas Jeromin, Richard Batrla-Utermann, Alcibiades Villarreal, Gabrielle Britton, Peter J. Snyder, Kim Henriksen, Paula Grammas, Veer GuptaRalph Martins, Harald Hampel, Biofluid Based Biomarker Professional Interest Area

Research output: Contribution to journalShort survey

Abstract

The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.

Original languageEnglish (US)
Pages (from-to)45-58
Number of pages14
JournalAlzheimer's and Dementia
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Alzheimer Disease
Biomarkers
Public-Private Sector Partnerships
Research
Neurodegenerative Diseases
Industry
Costs and Cost Analysis

Keywords

  • Alzheimer's disease
  • Biomarker
  • Blood
  • Cerebrospinal fluid
  • Context of use
  • Diagnosis
  • Diagnosis
  • Imaging

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Geriatrics and Gerontology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

O'Bryant, S. E., Mielke, M. M., Rissman, R. A., Lista, S., Vanderstichele, H., Zetterberg, H., ... Biofluid Based Biomarker Professional Interest Area (2017). Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer's and Dementia, 13(1), 45-58. https://doi.org/10.1016/j.jalz.2016.09.014

Blood-based biomarkers in Alzheimer disease : Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. / O'Bryant, Sid E.; Mielke, Michelle M.; Rissman, Robert A.; Lista, Simone; Vanderstichele, Hugo; Zetterberg, Henrik; Lewczuk, Piotr; Posner, Holly; Hall, James; Johnson, Leigh; Fong, Yiu Lian; Luthman, Johan; Jeromin, Andreas; Batrla-Utermann, Richard; Villarreal, Alcibiades; Britton, Gabrielle; Snyder, Peter J.; Henriksen, Kim; Grammas, Paula; Gupta, Veer; Martins, Ralph; Hampel, Harald; Biofluid Based Biomarker Professional Interest Area.

In: Alzheimer's and Dementia, Vol. 13, No. 1, 01.01.2017, p. 45-58.

Research output: Contribution to journalShort survey

O'Bryant, SE, Mielke, MM, Rissman, RA, Lista, S, Vanderstichele, H, Zetterberg, H, Lewczuk, P, Posner, H, Hall, J, Johnson, L, Fong, YL, Luthman, J, Jeromin, A, Batrla-Utermann, R, Villarreal, A, Britton, G, Snyder, PJ, Henriksen, K, Grammas, P, Gupta, V, Martins, R, Hampel, H & Biofluid Based Biomarker Professional Interest Area 2017, 'Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic', Alzheimer's and Dementia, vol. 13, no. 1, pp. 45-58. https://doi.org/10.1016/j.jalz.2016.09.014
O'Bryant, Sid E. ; Mielke, Michelle M. ; Rissman, Robert A. ; Lista, Simone ; Vanderstichele, Hugo ; Zetterberg, Henrik ; Lewczuk, Piotr ; Posner, Holly ; Hall, James ; Johnson, Leigh ; Fong, Yiu Lian ; Luthman, Johan ; Jeromin, Andreas ; Batrla-Utermann, Richard ; Villarreal, Alcibiades ; Britton, Gabrielle ; Snyder, Peter J. ; Henriksen, Kim ; Grammas, Paula ; Gupta, Veer ; Martins, Ralph ; Hampel, Harald ; Biofluid Based Biomarker Professional Interest Area. / Blood-based biomarkers in Alzheimer disease : Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. In: Alzheimer's and Dementia. 2017 ; Vol. 13, No. 1. pp. 45-58.
@article{f535ed9ea48d404ba3b486de0eb73c1a,
title = "Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic",
abstract = "The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.",
keywords = "Alzheimer's disease, Biomarker, Blood, Cerebrospinal fluid, Context of use, Diagnosis, Diagnosis, Imaging",
author = "O'Bryant, {Sid E.} and Mielke, {Michelle M.} and Rissman, {Robert A.} and Simone Lista and Hugo Vanderstichele and Henrik Zetterberg and Piotr Lewczuk and Holly Posner and James Hall and Leigh Johnson and Fong, {Yiu Lian} and Johan Luthman and Andreas Jeromin and Richard Batrla-Utermann and Alcibiades Villarreal and Gabrielle Britton and Snyder, {Peter J.} and Kim Henriksen and Paula Grammas and Veer Gupta and Ralph Martins and Harald Hampel and {Biofluid Based Biomarker Professional Interest Area}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.jalz.2016.09.014",
language = "English (US)",
volume = "13",
pages = "45--58",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Blood-based biomarkers in Alzheimer disease

T2 - Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

AU - O'Bryant, Sid E.

AU - Mielke, Michelle M.

AU - Rissman, Robert A.

AU - Lista, Simone

AU - Vanderstichele, Hugo

AU - Zetterberg, Henrik

AU - Lewczuk, Piotr

AU - Posner, Holly

AU - Hall, James

AU - Johnson, Leigh

AU - Fong, Yiu Lian

AU - Luthman, Johan

AU - Jeromin, Andreas

AU - Batrla-Utermann, Richard

AU - Villarreal, Alcibiades

AU - Britton, Gabrielle

AU - Snyder, Peter J.

AU - Henriksen, Kim

AU - Grammas, Paula

AU - Gupta, Veer

AU - Martins, Ralph

AU - Hampel, Harald

AU - Biofluid Based Biomarker Professional Interest Area

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.

AB - The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.

KW - Alzheimer's disease

KW - Biomarker

KW - Blood

KW - Cerebrospinal fluid

KW - Context of use

KW - Diagnosis

KW - Diagnosis

KW - Imaging

UR - http://www.scopus.com/inward/record.url?scp=85009063579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009063579&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2016.09.014

DO - 10.1016/j.jalz.2016.09.014

M3 - Short survey

C2 - 27870940

AN - SCOPUS:85009063579

VL - 13

SP - 45

EP - 58

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 1

ER -